UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
UCB And Biogen Present Phase 3 Data On Dapirolizumab Pegol, Showing Significant Lupus Activity Reduction
UCb和渤健公司公佈達皮羅利祖單抗第3期數據，顯示明顯的紅斑狼瘡活動減少
- Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activity
- A greater response was observed across multiple clinical endpoints among participants treated with DZP including 50% less severe disease flares compared to participants on standard of care alone
- Systemic Lupus Erythematosus is a chronic, debilitating autoimmune disease affecting multiple organ systems, primarily in women, for whom there is a significant need for additional treatment options
- Dapirolizumab pegol (DZP) 達到了其主要終點，顯示出在所有器官系統中，通過BICLA測量的疾病活動性，統計上和臨床上都有顯著改善。
- 相比僅接受標準治療的參與者，接受DZP治療的參與者在多個臨床終點上觀察到了更大的反應，包括嚴重疾病急性發作減少50%。
- 系統性紅斑狼瘡是一種慢性、使人衰弱的自身免疫疾病，主要影響多個器官系統，尤其是在女性中，對額外治療選項的需求很大。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間